Dr. Sheldon Greenfield, co-executive director of UCI’s Health Policy Research Institute, will lead the project with Sherrie H. Kaplan. Matt Herp / ADA

Irvine, Calif., Nov. 15, 2016 — University of California, Irvine health policy researchers have been awarded $1.2 million by the California Initiative to Advance Precision Medicine to develop more effective ways for prostate cancer patients and their physicians to customize treatment.

Dr. Sheldon Greenfield and Sherrie H. Kaplan, co-executive directors of UCI’s Health Policy Research Institute, will lead the project. It was one of six funded today by the state initiative, which was created in 2015 to provide the infrastructure and resources necessary to advance precision medicine-oriented data, tools and applications in California.

“This grant represents an exciting opportunity to link patient-reported disease burden with tumor biomarkers to evaluate the effectiveness of prostate cancer treatment,” said Greenfield, the Donald Bren Professor of Medicine at UCI. “We envision that study results will help doctors and patients tailor treatment based on a composite picture of the patient’s illness, tumor biology and personal circumstances.”

Prostate cancer is the most common cancer in men, with more than 200,000 new cases diagnosed each year in the U.S. It is the second-leading cause of cancer death in males and affects roughly 1 in 7 of them over their lifetime.

Sherrie H. Kaplan, co-executive director of UCI’s Health Policy Research Institute, will lead the project with Dr. Sheldon Greenfield. UCI
Sherrie H. Kaplan, co-executive director of UCI’s Health Policy Research Institute, will lead the project with Dr. Sheldon Greenfield.

The project will focus on improving risk predictions, including both the benefits and the potential harms of different treatment strategies for early-stage prostate cancer. Among the most pressing challenges that face physicians who care for men with prostate cancer is evaluating one’s potential benefit from treatment. As part of the two-year clinical study, prostate cancer patients will be given a detailed questionnaire that features 25 questions addressing myriad existing health issues to help determine the aggressiveness of treatment.

The final prognosis will be based on detailed patient characteristics, such as sociodemographic factors, health status and disease management burden, combined with traditional prostate cancer severity indicators and established genomic identifiers.

Greenfield expects that 600 patients from five Southern California-area hospitals will be enrolled. Along with the UCI personnel, the team – which has had considerable prior experience collaborating on research projects – will include investigators and patients from UCLA, Cedars-Sinai Medical Center, the Veterans Affairs Greater Los Angeles Healthcare System and the Veterans Affairs Long Beach Healthcare System.

“Right now, the evidence supports treatment decisions for the average patient. This study will give doctors much better data on which to base recommendations for individual patients,” said Kaplan, adding that this approach will be applicable to other cancers and chronic diseases.

The six projects funded today by the California Initiative to Advance Precision Medicine aim to promote customized healthcare by using data-driven tools and analysis to develop new diagnostics, therapies and insights into disease. The winning teams will join forces to utilize data across research, clinical, environmental and population health settings to better diagnose, treat, manage and prevent disease.

Projects based at UC Davis, UC San Francisco, Children’s Hospital Oakland Research Institute, Cedars-Sinai Medical Center and Sutter Health were also awarded grants.

The California Initiative to Advance Precision Medicine was launched by Gov. Jerry Brown last year and received additional funding in fiscal 2016-17. UC Health and UC San Francisco host the initiative with the Governor’s Office of Planning & Research.

About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 30,000 students and offers 192 degree programs. It’s located in one of the world’s safest and most economically vibrant communities and is Orange County’s second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit www.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit wp.communications.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.